An Irish veterinary biologics developer has announced positive results from a safety and efficacy study of a monoclonal antibody for the control of pain associated with osteoarthritis in dogs.

nexvet-logoNexvet Biopharma has completed the study of NV-01, the company’s anti-nerve growth factor monoclonal antibody therapy.

The primary endpoint achieved was a statistically significant (p=0.038) improvement over placebo in the assessed level of pain as measured using changes in client-specific outcome measures (CSOM) score between enrolment and day 28.

Additionally, NV-01 was found to be safe and well-tolerated, with no significant adverse safety signals observed in the study.

Positive results

Clinically meaningful magnitudes of benefit and statistically significant differences over placebo were also achieved for the majority of the secondary endpoints measured in the study. These included:

  • pain assessments measured using the validated pain scoring protocols CSOM
  • canine brief pain inventory at various points in time

Collectively, the results of this study constitute a substantial body of efficacy data that Nexvet intends to use as the basis of its planned submissions for marketing authorisations in both the US and Europe.

Nexvet chief executive Mark Heffernan said: “This is a tremendous outcome for Nexvet and we are particularly pleased to receive strong data supporting the long duration of efficacy following a single monthly injection – a key advantage for monoclonal antibody therapies over small molecules.

“This achievement is a testament to the power and potential of our proprietary PETization platform to produce effective 100% species-specific veterinary therapeutic candidates.”

View your activity >

Leave a Reply

Be the First to Comment!

Notify of
avatar

wpDiscuz

related content

The BVA says it is “appalled” at the vote by legislators to reintroduce the tail docking of certain classes of working dogs in Scotland.

4 mins

Research from the RVC has shown brachycephalic dogs are 11 times more susceptible to corneal ulcerative disease compared to non-brachycephalics.

4 mins

Staff from Vets4Pets and Petplan raise hundreds of pounds for Bath Cats and Dogs Home at the charity's annual kennel lock-in.

2 mins

Most practices have emerged from the dark ages, when postcards and the odd phone call were the only ways of communicating with clients. Dr Ernie Ward explains how modern methods are driving revenue growth, enhancing patient care and boosting client satisfaction.

25 mins

Vicky Robinson discusses how practice teams can work together to drive dental initiatives, the form they should take and the impact they can have on the bottom line.

16 mins

Veterinary surgeon Julian Peters has been honoured for decades of “unwavering dedication” to helping animals in need.

4 mins